Articles | Volume 6, issue 1
https://doi.org/10.5194/jbji-6-19-2020
© Author(s) 2020. This work is distributed under
the Creative Commons Attribution 4.0 License.Reply to Scheper and de Boer's comment on “Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France” by Becker et al. (2020)
Related authors
Cited articles
Becker, A., Kreitmann, L., Triffaut-Fillit, C., Valour, F., Mabrut, E., Forestier, E., Lesens, O., Cazorla, C., Descamps, S., Boyer, B., Chidiac, C., Lustig, S., Montbarbon, E., Batailler, C., and Ferry, T.: Duration of rifampin therapy is a key determinant of improved outcomes in early-onset acute prosthetic joint infection due to Staphylococcus treated with a debridement, antibiotics and implant retention (DAIR): a retrospective multicenter study in France, J. Bone Joint Infect., 5, 28–34, https://doi.org/10.7150/jbji.40333, 2020.
D'Agostino, R. B.: Propensity score methods for bias reduction in the
comparison of a treatment to a non-randomized control group,
Stat. Med., 17, 2265–2281,
https://doi.org/10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b, 1998.
Putter, H., Fiocco, M., and Geskus, R. B.: Tutorial in biostatistics: competing risks
and multi-state models, Stat. Med., 26, 2389–2430,
https://doi.org/10.1002/sim.2712, 2007.